Molecular determinations of EGFR and EML4-ALK on a single slide of NSCLC tissue

Paola Ulivi, Maurizio Puccetti, Laura Capelli, Elisa Chiadini, Sara Bravaccini, Daniele Calistri, Wainer Zoli, Dino Amadori, Piero Candoli

Research output: Contribution to journalArticle

Abstract

Introduction Tyrosine kinase inhibitors (TKIs) and anti-anaplastic lymphoma kinase (ALK) agents are highly effective for the treatment of non-small cell lung cancer (NSCLC) patients harbouring specific alterations, and molecular characterisation of the tumour is needed even when limited tumour material is available. Methods 20 patients with a known epidermal growth factor receptor (EGFR) gene status were enrolled: 10 had mutated and 10 had wild type tumours. FISH analysis was performed on one cytological or histological sample to determine EML4-ALK status, after which the same cells scraped off each slide were used to evaluate the EGFR status. Results In the 10 EGFR mutated patients, molecular analysis showed the same results as those obtained before the FISH test. One patient with an EGFR mutation also showed an EML4-ALK translocation, and both FISH-positive and FISH-negative cells maintained the EGFR mutation. Conclusions EGFR mutation analysis can be performed on the same sample previously submitted to the EML4-ALK FISH procedure.

Original languageEnglish
Pages (from-to)708-710
Number of pages3
JournalJournal of Clinical Pathology
Volume66
Issue number8
DOIs
Publication statusPublished - Aug 2013

Fingerprint

Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
Mutation
erbB-1 Genes
Neoplasms
Protein-Tyrosine Kinases
anaplastic lymphoma kinase
Therapeutics

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Molecular determinations of EGFR and EML4-ALK on a single slide of NSCLC tissue. / Ulivi, Paola; Puccetti, Maurizio; Capelli, Laura; Chiadini, Elisa; Bravaccini, Sara; Calistri, Daniele; Zoli, Wainer; Amadori, Dino; Candoli, Piero.

In: Journal of Clinical Pathology, Vol. 66, No. 8, 08.2013, p. 708-710.

Research output: Contribution to journalArticle

Ulivi, Paola ; Puccetti, Maurizio ; Capelli, Laura ; Chiadini, Elisa ; Bravaccini, Sara ; Calistri, Daniele ; Zoli, Wainer ; Amadori, Dino ; Candoli, Piero. / Molecular determinations of EGFR and EML4-ALK on a single slide of NSCLC tissue. In: Journal of Clinical Pathology. 2013 ; Vol. 66, No. 8. pp. 708-710.
@article{268ac40b63ea4a9eae6735c72fe25939,
title = "Molecular determinations of EGFR and EML4-ALK on a single slide of NSCLC tissue",
abstract = "Introduction Tyrosine kinase inhibitors (TKIs) and anti-anaplastic lymphoma kinase (ALK) agents are highly effective for the treatment of non-small cell lung cancer (NSCLC) patients harbouring specific alterations, and molecular characterisation of the tumour is needed even when limited tumour material is available. Methods 20 patients with a known epidermal growth factor receptor (EGFR) gene status were enrolled: 10 had mutated and 10 had wild type tumours. FISH analysis was performed on one cytological or histological sample to determine EML4-ALK status, after which the same cells scraped off each slide were used to evaluate the EGFR status. Results In the 10 EGFR mutated patients, molecular analysis showed the same results as those obtained before the FISH test. One patient with an EGFR mutation also showed an EML4-ALK translocation, and both FISH-positive and FISH-negative cells maintained the EGFR mutation. Conclusions EGFR mutation analysis can be performed on the same sample previously submitted to the EML4-ALK FISH procedure.",
author = "Paola Ulivi and Maurizio Puccetti and Laura Capelli and Elisa Chiadini and Sara Bravaccini and Daniele Calistri and Wainer Zoli and Dino Amadori and Piero Candoli",
year = "2013",
month = "8",
doi = "10.1136/jclinpath-2013-201502",
language = "English",
volume = "66",
pages = "708--710",
journal = "Journal of Clinical Pathology - Clinical Molecular Pathology",
issn = "0021-9746",
publisher = "BMJ Publishing Group",
number = "8",

}

TY - JOUR

T1 - Molecular determinations of EGFR and EML4-ALK on a single slide of NSCLC tissue

AU - Ulivi, Paola

AU - Puccetti, Maurizio

AU - Capelli, Laura

AU - Chiadini, Elisa

AU - Bravaccini, Sara

AU - Calistri, Daniele

AU - Zoli, Wainer

AU - Amadori, Dino

AU - Candoli, Piero

PY - 2013/8

Y1 - 2013/8

N2 - Introduction Tyrosine kinase inhibitors (TKIs) and anti-anaplastic lymphoma kinase (ALK) agents are highly effective for the treatment of non-small cell lung cancer (NSCLC) patients harbouring specific alterations, and molecular characterisation of the tumour is needed even when limited tumour material is available. Methods 20 patients with a known epidermal growth factor receptor (EGFR) gene status were enrolled: 10 had mutated and 10 had wild type tumours. FISH analysis was performed on one cytological or histological sample to determine EML4-ALK status, after which the same cells scraped off each slide were used to evaluate the EGFR status. Results In the 10 EGFR mutated patients, molecular analysis showed the same results as those obtained before the FISH test. One patient with an EGFR mutation also showed an EML4-ALK translocation, and both FISH-positive and FISH-negative cells maintained the EGFR mutation. Conclusions EGFR mutation analysis can be performed on the same sample previously submitted to the EML4-ALK FISH procedure.

AB - Introduction Tyrosine kinase inhibitors (TKIs) and anti-anaplastic lymphoma kinase (ALK) agents are highly effective for the treatment of non-small cell lung cancer (NSCLC) patients harbouring specific alterations, and molecular characterisation of the tumour is needed even when limited tumour material is available. Methods 20 patients with a known epidermal growth factor receptor (EGFR) gene status were enrolled: 10 had mutated and 10 had wild type tumours. FISH analysis was performed on one cytological or histological sample to determine EML4-ALK status, after which the same cells scraped off each slide were used to evaluate the EGFR status. Results In the 10 EGFR mutated patients, molecular analysis showed the same results as those obtained before the FISH test. One patient with an EGFR mutation also showed an EML4-ALK translocation, and both FISH-positive and FISH-negative cells maintained the EGFR mutation. Conclusions EGFR mutation analysis can be performed on the same sample previously submitted to the EML4-ALK FISH procedure.

UR - http://www.scopus.com/inward/record.url?scp=84880646431&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880646431&partnerID=8YFLogxK

U2 - 10.1136/jclinpath-2013-201502

DO - 10.1136/jclinpath-2013-201502

M3 - Article

C2 - 23533259

AN - SCOPUS:84880646431

VL - 66

SP - 708

EP - 710

JO - Journal of Clinical Pathology - Clinical Molecular Pathology

JF - Journal of Clinical Pathology - Clinical Molecular Pathology

SN - 0021-9746

IS - 8

ER -